Thu, August 11, 2022
Wed, August 10, 2022
Tue, August 9, 2022
Mon, August 8, 2022

Vamil Divan Maintained (ACAD) at Hold with Decreased Target to $19 on, Aug 10th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-19-on-aug-10th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Vamil Divan of Mizuho, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Decreased Target from $27 to $19 on, Aug 10th, 2022.

Vamil has made no other calls on ACAD in the last 4 months.



There are 8 other peers that have a rating on ACAD. Out of the 8 peers that are also analyzing ACAD, 3 agree with Vamil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Decreased Target to $18 on, Tuesday, August 9th, 2022
  • Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $15 on, Monday, August 8th, 2022
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $19 on, Tuesday, June 21st, 2022


These are the ratings of the 5 analyists that currently disagree with Vamil


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $25 on, Tuesday, August 9th, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $21 on, Tuesday, August 9th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $21 on, Tuesday, August 9th, 2022
  • Ritu Baral of "Cowen & Co." Maintained at Buy with Decreased Target to $21 on, Monday, August 8th, 2022
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022

Publication Contributing Sources